Similarly, securin immunopositivity predicted the disease outcome among patients with large tumour size (>3 cm in diameter) when adjusted for patient's age and nodal status (P=0.040, HR 3.8, 95% CI 1.1–13.7). The gene discussed is PTTG1; the disease is neoplasm.